The 2 analysts offering 12-month price forecasts for Atossa Therapeutics Inc have a median target of 4.75, with a high estimate of 5.50 and a low estimate of 4.00. The median estimate represents a +539.21% increase from the last price of 0.74.
The current consensus among 3 polled investment analysts is to Buy stock in Atossa Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.07
Reporting Date Mar 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.